rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TNYA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Tenaya Therapeutics CMO Tingley Whittemore sells $1,033 in stock
      2h agoInvesting.comTNYA
      Tenaya Therapeutics earnings beat by $0.02, revenue topped estimates
      Nov 5Investing.comTNYA
      Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinanceTNYA
      Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 4Yahoo FinanceTNYA
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailTNYA
      Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

      RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease,

      Sep 14Yahoo FinanceTNYA
      Tenaya at H.C. Wainwright conference: gene therapy data build
      Sep 11Investing.comTNYA
      Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

      SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will host investor meetings at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026 and the Morgan Stanley 24th Annual Global Healthcare

      Sep 3Yahoo FinanceTNYA
      Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

      All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two...

      Aug 28BarchartTNYA

      This is the newest page. Registered accounts read further back.